Comparative Pharmacology
Head-to-head clinical analysis: SYMADINE versus VISTIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SYMADINE versus VISTIDE.
SYMADINE vs VISTIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
SYMADINE (amantadine) is a tricyclic amine that inhibits influenza A virus replication by blocking the viral M2 ion channel, which prevents uncoating of viral RNA. It also increases dopamine release and inhibits dopamine reuptake in the CNS, providing antiparkinsonian effects.
Cidofovir is a nucleotide analogue that inhibits viral DNA polymerase by incorporating into viral DNA and causing chain termination, with selectivity for cytomegalovirus (CMV) DNA polymerase.
100 mg orally every 12 hours; immediate-release formulation.
5 mg/kg intravenously once weekly for 2 consecutive weeks, then every other week thereafter.
None Documented
None Documented
The terminal elimination half-life is approximately 24 hours in patients with normal renal function. In patients with renal impairment (CrCl <50 mL/min), the half-life is significantly prolonged, requiring dose adjustment. The long half-life allows for once-daily dosing.
Terminal elimination half-life is approximately 1.5-2 hours in patients with normal renal function. In patients with renal impairment, the half-life can extend to 5-10 hours or longer, necessitating dose adjustment based on creatinine clearance.
Renal elimination of unchanged drug accounts for approximately 90% of the administered dose. Biliary/fecal excretion is minimal (<5%).
Primarily renal excretion via glomerular filtration and active tubular secretion. Approximately 90-95% of the dose is excreted unchanged in the urine within 24 hours. Biliary/fecal excretion accounts for <5%.
Category C
Category C
Antiviral and Antiparkinsonian
Antiviral